Lyell Immunopharma (LYEL) Enterprise Value (2021 - 2026)

Lyell Immunopharma has reported Enterprise Value for 7 years, with the latest figure at -$254.0 million in Q1 2026.

• Quarterly Enterprise Value rose 15.66% year-over-year to -$254.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$254.0 million (up 15.66% YoY) and the FY2025 annual result came in at -$247.2 million, up 33.28% from the prior year.
• Enterprise Value declined to -$254.0 million in Q1 2026 per LYEL's latest filing, from -$247.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$247.2 million in Q4 2025 and troughed at -$655.6 million in Q2 2022.
• A 5-year average of -$477.4 million and a median of -$526.3 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 151.22% in 2022, then soared 43.64% in 2025.
• Over 5 years, Enterprise Value stood at -$640.2 million in 2022, then gained by 14.67% to -$546.2 million in 2023, then soared by 32.17% to -$370.5 million in 2024, then surged by 33.28% to -$247.2 million in 2025, then slipped by 2.75% to -$254.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$254.0 million, -$247.2 million, and -$319.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.